Lys Therapeutics secured €25 million to advance LYS241, a monoclonal antibody targeting pathological interactions between tissue plasminogen activator and NMDA receptors. The approach addresses blood-brain barrier dysfunction and neuroinflammation in Parkinson's disease and ischemic stroke by preserving normal receptor function while blocking disease-driving signaling.
Key Points
- LYS241 selectively blocks pathological TPA-NMDA interactions while preserving physiological function
- Funding supports Phase 1a/1b biomarker-rich trials in healthy volunteers and patient cohorts
- Mechanism targets blood-brain barrier dysfunction, neuroinflammation, and excitotoxicity in neurodeg
Longevity Analysis
This therapeutic strategy reflects a precision approach to neurodegeneration that distinguishes between pathological and protective signaling. Rather than broad immunosuppression or receptor antagonism, LYS241 preserves normal neural function while interrupting specific damage pathways—a distinction that matters for long-term neural health. The focus on blood-brain barrier integrity and neuroinflammatory resolution directly addresses mechanisms underlying both acute events like stroke and progressive neurodegeneration, positioning interventions that work with the brain's repair capacity rather than against it.
Original published by LT Wire.